JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 23, 2008; DOI: 10.1124/jpet.108.144444


0022-3565/08/3273-872-883$20.00
JPET 327:872-883, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.108.144444v1
327/3/872    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Xiang, K.
Right arrow Articles by Tietz, E. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Xiang, K.
Right arrow Articles by Tietz, E. I.

NEUROPHARMACOLOGY

Chronic Benzodiazepine Administration Potentiates High Voltage-Activated Calcium Currents in Hippocampal CA1 Neurons

Kun Xiang, Damien E. Earl, Kathleen M. Davis, David R. Giovannucci, L. John Greenfield, Jr., and Elizabeth I. Tietz

Departments of Physiology and Pharmacology (K.X., D.E.E., K.M.D., L.J.G., E.I.T.), Neurosciences (D.R.G.), Neurology (L.J.G.), and Cellular and Molecular Neurobiology Program (K.X., D.E.E., K.M.D.), University of Toledo College of Medicine, Toledo, Ohio

Signs of physical dependence as a consequence of long-term drug use and a moderate abuse liability limit benzodiazepine clinical usefulness. Growing evidence suggests a role for voltage-gated calcium channel (VGCC) regulation in mediating a range of chronic drug effects from drug withdrawal phenomena to dependence on a variety of drugs of abuse. High voltage-activated (HVA) calcium currents were measured in whole-cell recordings from acutely isolated hippocampal CA1 neurons after a 1-week flurazepam (FZP) treatment that results in withdrawal-anxiety. An ~1.8-fold increase in Ca2+ current density was detected immediately after and up to 2 days but not 3 or 4 days after drug withdrawal. Current density was unchanged after acute desalkyl-FZP treatment. A significant negative shift of the half-maximal potential of activation of HVA currents was also observed but steady-state inactivation remained unchanged. FZP and diazepam showed use- and concentration-dependent inhibition of Ca2+ currents in hippocampal cultured cells following depolarizing trains (FZP, IC50 = 1.8 µM; diazepam, IC50 = 36 µM), pointing to an additional mechanism by which benzodiazepines modulate HVA Ca2+ channels. Systemic preinjection of nimodipine (10 mg/kg), an L-type (L)-VGCC antagonist, prevented the benzodiazepine-induced increase in {alpha}-amino-3-hydroxy-5-methylisoxasole-4-propionic acid receptor (AMPAR)-mediated miniature excitatory postsynaptic current in CA1 neurons 2 days after FZP withdrawal, suggesting that AMPAR potentiation, previously linked to withdrawal-anxiety may require enhanced L-VGCC-mediated Ca2+ influx. Taken together with prior work, these findings suggest that enhanced Ca2+ entry through HVA Ca2+ channels may contribute to hippocampal AMPAR plasticity and serve as a potential mechanism underlying benzodiazepine physical dependence.


Received for publication August 6, 2008
Accepted September 22, 2008.

Address correspondence to: Dr. Elizabeth I. Tietz, Department of Physiology and Pharmacology, University of Toledo College of Medicine (formerly Medical University of Ohio), University of Toledo Health Science Campus, 3000 Arlington Ave., Mailstop 1008, Toledo, OH 43614. E-mail: liz.tietz{at}utoledo.edu







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.